Ku-0063794 is a specific inhibitor of the mammalian target of rapamycin (mTOR)

Biochemical Journal

Volumn 421, Issue 1, 2009, Pages 29-42

  García Martínez, Juan M ^a   Moran, Jennifer ^a   Clarke, Rosemary G ^a   Gray, Alex ^a   Cosulich, Sabina C ^b   Chresta, Christine M ^b   Alessi, Dario R ^a  

^a UNIVERSITY OF DUNDEE   (United Kingdom)

^b ASTRAZENECA   (United Kingdom)

Author keywords

Akt protein kinase B (PKB); Cancer; Kinase inhibitor; P70 ribosomal S6 kinase (S6K); Phosphoinositide 3 kinase (PI3K); Serum and glucocorticoid protein kinase (SGK)

Indexed keywords

AKT/PROTEIN KINASE B (PKB); CANCER; KINASE INHIBITOR; P70 RIBOSOMAL S6 KINASE (S6K); PHOSPHOINOSITIDE 3-KINASE (PI3K); SERUM AND GLUCOCORTICOID PROTEIN KINASE (SGK);

ANTIBIOTICS; BODY FLUIDS; CELL CULTURE; CELL GROWTH; CELL MEMBRANES; GROWTH KINETICS; HYDROPHOBICITY; MAMMALS; TISSUE;

PHOSPHORYLATION;

INITIATION FACTOR 4E BINDING PROTEIN 1; KU 0063794; MAMMALIAN TARGET OF RAPAMYCIN; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHOINOSITIDE DEPENDENT PROTEIN KINASE 1; PROTEIN KINASE; PROTEIN KINASE B; PROTEIN SUBUNIT; S6 KINASE; SERINE; THREONINE; UNCLASSIFIED DRUG; CRTC2 PROTEIN, HUMAN; MORPHOLINE DERIVATIVE; MTORC1 PROTEIN, HUMAN; PYRIMIDINE DERIVATIVE; TRANSCRIPTION FACTOR;

ANIMAL CELL; ARTICLE; CANCER THERAPY; CELL CYCLE ARREST; CELL CYCLE G1 PHASE; CELL GROWTH; CELL MEMBRANE PERMEABILITY; CELL STRAIN HEK293; CONCENTRATION RESPONSE; CONFORMATIONAL TRANSITION; CONTROLLED STUDY; DRUG MECHANISM; DRUG STRUCTURE; EMBRYO; EMBRYO CELL; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME PHOSPHORYLATION; ENZYME SUBSTRATE; FIBROBLAST; HELA CELL; HUMAN; HUMAN CELL; HYDROPHOBICITY; IC 50; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN DEPHOSPHORYLATION; PROTEIN FUNCTION; PROTEIN MOTIF; PROTEIN PHOSPHORYLATION; STRUCTURE ACTIVITY RELATION; ANIMAL; CELL LINE; CELL PROLIFERATION; CHEMISTRY; DRUG ANTAGONISM; DRUG EFFECT; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; METABOLISM;

EUKARYOTA; MAMMALIA;

ANIMALS; CELL LINE; CELL PROLIFERATION; FIBROBLASTS; G1 PHASE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; HUMANS; MICE; MORPHOLINES; PYRIMIDINES; TRANSCRIPTION FACTORS;

EID: 67650312583     PISSN: 02646021     EISSN: 14708728     Source Type: Journal    
DOI: 10.1042/BJ20090489     Document Type: Article

References (67)

1. Wullschleger, S., Loewith, R. and Hall, M. N. (2006) TOR signaling in growth and metabolism. Cell 124, 471-484
2. Sarbassov, D. D., Ali, S. M. and Sabatini, D. M. (2005) Growing roles for the mTOR pathway. Curr. Opin. Cell Biol. 17, 596-603
3. Loewith, R., Jacinto, E., Wullschleger, S., Lorberg, A., Crespo, J. L., Bonenfant, D., Oppliger, W., Jenoe, P. and Hall, M. N. (2002) Two TOR complexes, only one of which is rapamycin sensitive, have distinct roles in cell growth control. Mol. Cell 10, 457-468
4. Hara, K., Maruki, Y., Long, X., Yoshino, K., Oshiro, N., Hidayat, S., Tokunaga, C., Avruch, J. and Yonezawa, K. (2002) Raptor, a binding partner of target of rapamycin (TOR), mediates TOR action. Cell 110 177-189
5. Kim, D. H., Sarbassov, D. D., Ali, S. M., King, J. E., Latek, R. R., Erdjument-Bromage, H., Tempst, P. and Sabatini, D. M. (2002) mTOR interacts with raptor to form a nutrient-sensitive complex that signals to the cell growth machinery. Cell 110, 163-175
6. Hay, N. and Sonenberg, N. (2004) Upstream and downstream of mTOR. Genes Dev. 18, 1926-1945
7. Sancak, Y., Thoreen, C. C., Peterson, T. R., Lindquist, R. A., Kang, S. A., Spooner, E., Carr, S. A. and Sabatini, D. M. (2007) PRAS40 is an insulin-regulated inhibitor of the mTORC1 protein kinase. Mol. Cell 25, 903-915
8. Nicklin, P., Bergman, P., Zhang, B., Triantafellow, E., Wang, H., Nyfeler, B., Yang, H., Hild, M., Kung, C., Wilson, C. et al. (2009) Bidirectional transport of amino acids regulates mTOR and autophagy. Cell 136, 521-534
9. Sancak, Y., Peterson, T. R., Shaul, Y. D., Lindquist, R. A., Thoreen, C. C., Bar-Peled, L. and Sabatini, D. M. (2008) The Rag GTPases bind raptor and mediate amino acid signaling to mTORC1. Science 320, 1496-1501
10. Kim, E., Goraksha-Hicks, P., Li, L., Neufeld, T. P. and Guan, K. L. (2008) Regulation of TORC1 by Rag GTPases in nutrient response. Nat. Cell Biol. 10, 935-945
11. Alessi, D. R., Sakamoto, K. and Bayascas, J. R. (2006) LKB1-dependent signaling pathways. Annu. Rev. Biochem. 75, 137-163
12. Jacinto, E., Loewith, R., Schmidt, A., Lin, S., Ruegg, M. A., Hall, A. and Hall, M. N. (2004) Mammalian TOR complex 2 controls the actin cytoskeleton and is rapamycin insensitive. Nat. Cell Biol. 6, 1122-1128
13. Sarbassov, D. D., Ali, S. M., Kim, D. H., Guertin, D. A., Latek, R. R., Erdjument-Bromage, H., Tempst, P. and Sabatini, D. M. (2004) Rictor, a novel binding partner of mTOR, defines a rapamycin-insensitive and raptor-independent pathway that regulates the cytoskeleton. Curr. Biol. 14, 1296-1302
14. Yang, Q., Inoki, K., Ikenoue, T. and Guan, K. L. (2006) Identification of Sin1 as an essential TORC2 component required for complex formation and kinase activity. Genes Dev. 20, 2820-2832
15. Frias, M. A., Thoreen, C. C., Jaffe, J. D., Schroder, W., Sculley, T., Carr, S. A. and Sabatini, D. M. (2006) mSin1 is necessary for Akt/PKB phosphorylation, and its isoforms define three distinct mTORC2s. Curr. Biol. 16, 1865-1870
16. Jacinto, E., Facchinetti, V., Liu, D., Soto, N., Wei, S., Jung, S. Y., Huang, Q., Qin, J. and Su, B. (2006) SIN1/MIP1 maintains rictor-mTOR complex integrity and regulates Akt phosphorylation and substrate specificity. Cell 127, 125-137
17. Guertin, D. A., Stevens, D. M., Thoreen, C. C., Burds, A. A., Kalaany, N. Y., Moffat, J., Brown, M., Fitzgerald, K. J. and Sabatini, D. M. (2006) Ablation in mice of the mTORC components raptor, rictor, or mLST8 reveals that mTORC2 is required for signaling to Akt-FOXO and PKCα, but not S6K1. Dev. Cell 11, 859-871
18. Pearce, L. R., Huang, X., Boudeau, J., Pawlowski, R., Wullschleger, S., Deak, M., Ibrahim, A. F., Gourlay, R., Magnuson, M. A. and Alessi, D. R. (2007) Identification of Protor as a novel Rictor-binding component of mTOR complex-2. Biochem. J. 405, 513-522
19. Mora, A., Komander, D., Van Aalten, D. M. and Alessi, D. R. (2004) PDK1, the master regulator of AGC kinase signal transduction. Semin. Cell Dev. Biol. 15, 161-170
20. Sarbassov, D. D., Guertin, D. A., Ali, S. M. and Sabatini, D. M. (2005) Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex. Science 307, 1098-1101
21. Garcia-Martinez, J. M. and Alessi, D. R. (2008) mTOR complex-2 (mTORC2) controls hydrophobic motif phosphorylation and activation of serum and glucocorticoid induced protein kinase-1 (SGK1). Biochem. J. 416, 375-385
22. Parekh, D., Ziegler, W., Yonezawa, K., Hara, K. and Parker, P. J. (1999) Mammalian TOR controls one of two kinase pathways acting upon nPKCδ and nPKCε. J. Biol. Chem. 274, 34758-34764
23. Biondi, R. M. (2004) Phosphoinositide-dependent protein kinase 1, a sensor of protein conformation. Trends Biochem. Sci. 29, 136-142
24. Alessi, D. R., Deak, M., Casamayor, A., Caudwell, F. B., Morrice, N., Norman, D. G., Gaffney, P., Reese, C. B., MacDougall, C. N., Harbison, D. et al. (1997) 3-Phosphoinositide-dependent protein kinase-1 (PDK1): structural and functional homology with the Drosophila DSTPK61 kinase. Curr. Biol. 7, 776-789
25. Alessi, D. R., Kozlowski, M. T., Weng, Q. P., Morrice, N. and Avruch, J. (1998) 3-Phosphoinositide-dependent protein kinase 1 (PDK1) phosphorylates and activates the p70 S6 kinase in vivo and in vitro. Curr. Biol. 8, 69-81
26. Facchinetti, V., Ouyang, W., Wei, H., Soto, N., Lazorchak, A., Gould, C., Lowry, C., Newton, A. C., Mao, Y., Miao, R. Q. et al. (2008) The mammalian target of rapamycin complex 2 controls folding and stability of Akt and protein kinase C. EMBO J. 27, 1932-1943
27. Ikenoue, T., Inoki, K., Yang, Q., Zhou, X. and Guan, K. L. (2008) Essential function of TORC2 in PKC and Akt turn motif phosphorylation, maturation and signalling. EMBO J. 27, 1919-1931
28. Hara, K., Yonezawa, K., Weng, Q. P., Kozlowski, M. T., Belham, C. and Avruch, J. (1998) Amino acid sufficiency and mTOR regulate p70 S6 kinase and eIF-4E BP1 through a common effector mechanism. J. Biol. Chem. 273, 14484-14494
29. Erratum (1998) J. Biol. Chem. 273, 22160
30. Shiota, C., Woo, J. T., Lindner, J., Shelton, K. D. and Magnuson, M. A. (2006) Multiallelic disruption of the rictor gene in mice reveals that mTOR complex 2 is essential for fetal growth and viability. Dev. Cell 11, 583-589
31. Lizcano, J. M., Deak, M., Morrice, N., Kieloch, A., Hastie, C. J., Dong, L., Schutkowski, M., Reimer, U. and Alessi, D. R. (2002) Molecular basis for the substrate specificity of NIMA-related kinase-6 (NEK6). Evidence that NEK6 does not phosphorylate the hydrophobic motif of ribosomal S6 protein kinase and serum- and glucocorticoid-induced protein kinase in vivo. J. Biol. Chem. 277, 27839-27849
32. Collins, B. J., Deak, M., Murray-Tait, V. and Alessi, D. R. (2005) In vivo role of the phosphate-binding groove of PDK1 defined by knockin mutation. J. Cell Sci. 118, 5023-5034
33. Durocher, Y., Perret, S. and Kamen, A. (2002) High-level and high-throughput recombinant protein production by transient transfection of suspension-growing human 293-EBNA1 cells. Nucleic Acids Res. 30 E9
34. Gray, A., Olsson, H., Batty, I. H., Priganica, L. and Peter Downes, C. (2003) Nonradioactive methods for the assay of phosphoinositide 3-kinases and phosphoinositide phosphatases and selective detection of signaling lipids in cell and tissue extracts. Anal. Biochem. 313, 234-245
35. Bain, J., Plater, L., Elliott, M., Shpiro, N., Hastie, C. J., McLauchlan, H., Klevernic, I., Arthur, J. S., Alessi, D. R. and Cohen, P. (2007) The selectivity of protein kinase inhibitors: A further update. Biochem. J. 408, 297-315
36. Kobayashi, T. and Cohen, P. (1999) Activation of serum- and glucocorticoid-regulated protein kinase by agonists that activate phosphatidylinositide 3-kinase is mediated by 3- phosphoinositide-dependent protein kinase-1 (PDK1) and PDK2. Biochem. J. 339, 319-328
37. Copp, J., Manning, G. and Hunter, T. (2009) TORC-specific phosphorylation of mammalian target of rapamycin (mTOR): Phospho-Ser2481 is a marker for intact mTOR signaling complex 2. Cancer Res. 69, 1821-1827
38. Chiang, G. G. and Abraham, R. T. (2005) Phosphorylation of mammalian target of rapamycin (mTOR) at Ser-2448 is mediated by p70S6 kinase. J. Biol. Chem. 280, 25485-25490
39. Holz, M. K. and Blenis, J. (2005) Identification of S6 kinase 1 as a novel mammalian target of rapamycin (mTOR)-phosphorylating kinase. J. Biol. Chem. 280, 26089-26093
40. Kovacina, K. S., Park, G. Y., Bae, S. S., Guzzetta, A. W., Schaefer, E., Birnbaum, M. J. and Roth, R. A. (2003) Identification of a proline-rich Akt substrate as a 14-3-3 binding partner. J. Biol. Chem. 278, 10189-10194
41. Cross, D. A., Alessi, D. R., Cohen, P., Andjelkovich, M. and Hemmings, B. A. (1995) Inhibition of glycogen synthase kinase-3 by insulin mediated by protein kinase B. Nature 378, 785-789
42. Brunet, A., Bonni, A., Zigmond, M. J., Lin, M. Z., Juo, P., Hu, L. S., Anderson, M. J., Arden, K. C., Blenis, J. and Greenberg, M. E. (1999) Akt promotes cell survival by phosphorylating and inhibiting a Forkhead transcription factor. Cell 96, 857-868
43. Jones, K. T., Greer, E. R., Pearce, D. and Ashrafi, K. (2009) Rictor/ TORC2 regulates Caenorhabditis elegans fat storage, body size, and development through sgk-1. PLoS Biol 7, e60
44. Soukas, A. A., Kane, E. A., Carr, C. E., Melo, J. A. and Ruvkun, G. (2009) Rictor/TORC2 regulates fat metabolism, feeding, growth, and life span in Caenorhabditis elegans. Genes Dev. 23, 496-511
45. Murray, J. T., Campbell, D. G., Morrice, N., Auld, G. C., Shpiro, N., Marquez, R., Peggie, M., Bain, J., Bloomberg, G. B., Grahammer, F. et al. (2004) Exploitation of KESTREL to identify NDRG family members as physiological substrates for SGK1 and GSK3. Biochem. J. 384, 477-488
46. Green, C. J., Goransson, O., Kular, G. S., Leslie, N. R., Gray, A., Alessi, D. R., Sakamoto, K. and Hundal, H. S. (2008) Use of Akt inhibitor and a drug-resistant mutant validates a critical role for protein kinase B/Akt in the insulin-dependent regulation of glucose and system A amino acid uptake. J. Biol. Chem. 283, 27653-27667
47. Barrett, S. D., Bridges, A. J., Dudley, D. T., Saltiel, A. R., Fergus, J. H., Flamme, C. M., Delaney, A. M., Kaufman, M., LePage, S., Leopold, W. R. et al. (2008) The discovery of the benzhydroxamate MEK inhibitors CI-1040 and PD 0325901. Bioorg. Med. Chem. Lett. 18, 6501-6504
48. Manning, G., Whyte, D. B., Martinez, R., Hunter, T. and Sudarsanam, S. (2002) The protein kinase complement of the human genome. Science 298 1912-1934
49. Brunn, G. J., Williams, J., Sabers, C., Wiederrecht, G., Lawrence, Jr, J. C. and Abraham, R. T. (1996) Direct inhibition of the signaling functions of the mammalian target of rapamycin by the phosphoinositide 3-kinase inhibitors, wortmannin and LY294002. EMBO J. 15, 5256-5267
50. Fan, Q. W., Knight, Z. A., Goldenberg, D. D., Yu, W., Mostov, K. E., Stokoe, D., Shokat, K. M. and Weiss, W. A. (2006) A dual PI3 kinase/mTOR inhibitor reveals emergent efficacy in glioma. Cancer Cell 9, 341-349
51. Maira, S. M., Stauffer, F., Brueggen, J., Furet, P., Schnell, C., Fritsch, C., Brachmann, S., Chene, P., De Pover, A., Schoemaker, K. et al. (2008) Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent in vivo antitumor activity. Mol. Cancer Ther. 7, 1851-1863
52. Folkes, A. J., Ahmadi, K., Alderton, W. K., Alix, S., Baker, S. J., Box, G., Chuckowree, I. S., Clarke, P. A., Depledge, P., Eccles, S. A. et al. (2008) The identification of 2-(1H indazol-4-yl)-6-(4-methanesulfonyl-piperazin-1-ylmethyl)-4-morpholin- 4-yl-thieno[3,2-d]pyrimidine (GDC-0941) as a potent, selective, orally bioavailable inhibitor of class I PI3 kinase for the treatment of cancer. J. Med. Chem. 51, 5522-5532
53. Feldman, M. E., Apsel, B., Uotila, A., Loewith, R., Knight, Z. A., Ruggero, D. and Shokat, K. M. (2009) Active-site inhibitors of mTOR target rapamycin-resistant outputs of mTORC1 and mTORC2. PLoS Biol. 7 e38
54. Thoreen, C. C., Kang, S. A., Chang, J. W., Liu, Q., Zhang, J., Gao, Y., Reichling, L. J., Sim, T., Sabatini, D. M. and Gray, N. S. (2009) An ATP-competitive mTOR inhibitor reveals rapamycin-insensitive functions of mTORC1. J. Biol. Chem. 284, 8023-8032
55. Alessi, D. R., Pearce, L. R. and Garcia-Martinez, J. M. (2009) New insights into mTOR Signaling: MTORC2 and beyond. Science Signaling 2 pe27
56. Alessi, D. R., Andjelkovic, M., Caudwell, B., Cron, P., Morrice, N., Cohen, P. and Hemmings, B. A. (1996) Mechanism of activation of protein kinase B by insulin and IGF-1. EMBO J. 15, 6541-6551
57. Williams, M. R., Arthur, J. S., Balendran, A., van der Kaay, J., Poli, V., Cohen, P. and Alessi, D. R. (2000) The role of 3-phosphoinositide-dependent protein kinase 1 in activating AGC kinases defined in embryonic stem cells. Curr. Biol. 10, 439-448
58. Mora, A., Davies, A. M., Bertrand, L., Sharif, I., Budas, G. R., Jovanovic, S., Mouton, V., Kahn, C. R., Lucocq, J. M., Gray, G. A. et al. (2003) Deficiency of PDK1 in cardiac muscle results in heart failure and increased sensitivity to hypoxia. EMBO J. 22, 4666-4676
59. Mora, A., Lipina, C., Tronche, F., Sutherland, C. and Alessi, D. R. (2005) Deficiency of PDK1 in liver results in glucose intolerance, impairment of insulin-regulated gene expression and liver failure. Biochem. J. 385, 639-648
60. Collins, B. J., Deak, M., Arthur, J. S., Armit, L. J. and Alessi, D. R. (2003) In vivo role of the PIF-binding docking site of PDK1 defined by knock-in mutation. EMBO J. 22, 4202-4211
61. Collins, B. J., Deak, M., Murray-Tait, V., Storey, K. G. and Alessi, D. R. (2005) In vivo role of the phosphate groove of PDK1 defined by knockin mutation. J. Cell Sci. 118, 5023-5034
62. Bayascas, J. R., Sakamoto, K., Armit, L., Arthur, J. S. and Alessi, D. R. (2006) Evaluation of approaches to generate PDK1 tissue specific knock-in mice. J. Biol. Chem. 281, 28772-28781
63. Bayascas, J. R., Wullschleger, S., Sakamoto, K., Garcia-Martinez, J. M., Clacher, C., Komander, D., van Aalten, D. M., Boini, K. M., Lang, F., Lipina, C. et al. (2008) Mutation of the PDK1 PH domain inhibits protein kinase B/Akt, leading to small size and insulin resistance. Mol. Cell Biol. 28, 3258-3272
64. Stockman, B. J., Kothe, M., Kohls, D., Weibley, L., Connolly, B. J., Sheils, A. L., Cao, Q., Cheng, A. C., Yang, L., Kamath, A. V. et al. (2009) Identification of allosteric PIF-pocket ligands for PDK1 using NMR-based fragment screening and 1H-15N TROSY experiments. Chem. Biol. Drug Des. 73, 179-188
65. Engel, M., Hindie, V., Lopez-Garcia, L. A., Stroba, A., Schaeffer, F., Adrian, I., Imig, J., Idrissova, L., Nastainczyk, W., Zeuzem, S. et al. (2006) Allosteric activation of the protein kinase PDK1 with low molecular weight compounds. EMBO J. 25, 5469-5480
66. Yang, J., Cron, P., Thompson, V., Good, V. M., Hess, D., Hemmings, B. A. and Barford, D. (2002) Molecular mechanism for the regulation of protein kinase B/Akt by hydrophobic motif phosphorylation. Mol. Cell 9, 1227-1240
67. Baldo, P., Cecco, S., Giacomin, E., Lazzarini, R., Ros, B. and Marastoni, S. (2008) mTOR pathway and mTOR inhibitors as agents for cancer therapy. Curr. Cancer Drug Targets 8, 647-665